-transparent.png){kind=logo}
OBJECTIVE Medullary thyroid carcinoma like other neuroendocrine tumors express somatostatin receptors. METHODS Antisecretory and antiproliferative effects of the long-acting somatostatin analog octreotide should be evaluated in a prospective study in 7 patients with metastasizing medullary thyroid carcinoma. RESULTS Treatment with octreotide in daily doses between 100 and 1000 micrograms resulted in a remission lasting up to 12 months in 2 of 7 patients. A decrease of tumor marker levels was observed in 2 patients, improvement of diarrhea and a remission of a lymph node metastasis in one of these. CONCLUSIONS This minor therapeutic effect may be due to the relatively low density of receptors or with a low affinity of the receptors expressed in medullary thyroid carcinoma to octreotide.
K Frank-Raue, and
F Raue, and
R Ziegler
August 1990,
Clinical endocrinology,
K Frank-Raue, and
F Raue, and
R Ziegler
February 1999,
Deutsche medizinische Wochenschrift (1946),
K Frank-Raue, and
F Raue, and
R Ziegler
December 1995,
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR),
K Frank-Raue, and
F Raue, and
R Ziegler
June 1989,
Wiener klinische Wochenschrift,
K Frank-Raue, and
F Raue, and
R Ziegler
January 1989,
Henry Ford Hospital medical journal,
K Frank-Raue, and
F Raue, and
R Ziegler
December 1995,
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR),
K Frank-Raue, and
F Raue, and
R Ziegler
June 1989,
American family physician,
K Frank-Raue, and
F Raue, and
R Ziegler
July 1992,
Deutsche medizinische Wochenschrift (1946),
K Frank-Raue, and
F Raue, and
R Ziegler
January 1993,
Medizinische Klinik (Munich, Germany : 1983),
K Frank-Raue, and
F Raue, and
R Ziegler
December 2004,
Journal of experimental & clinical cancer research : CR,
